These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24620420)

  • 1. Your business in court and at federal agencies: 2010 - 2011.
    Reiss JB; Crowder D; Simons B; Pleskov I; Davis T; Nugent P
    Food Drug Law J; 2012; 67(2):243-92, iii. PubMed ID: 24620420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Your business in court and at Federal agencies: 2011-2012.
    Reiss JB; Crowder D; McCabe B; DeFeo M; Rifin M; Talbot M
    Food Drug Law J; 2013; 68(1):1-51, i. PubMed ID: 24640636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Your business in court: 2009-2010.
    Reiss JB; Hall CR; Wartman GJ
    Food Drug Law J; 2011; 66(2):139-81, i. PubMed ID: 24505838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
    Murdey J
    Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marketing nutrition & health-related benefits of food & beverage products: enforcement, litigation & liability issues.
    Roller S; Pippins R
    Food Drug Law J; 2010; 65(3):447-69, i. PubMed ID: 24479235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FDA may not regulate tobacco products as "drugs" or as "medical devices".
    Merrill RA
    Duke Law J; 1998 Apr; 47(6):1071-94. PubMed ID: 10557545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importing a change in diet: the proposed food safety law of 2010 and the possible impact on importers and international trade.
    May SG
    Food Drug Law J; 2010; 65(1):1-35, i. PubMed ID: 24475533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is tobacco a drug? Administrative agencies as common law courts.
    Sunstein CR
    Duke Law J; 1998 Apr; 47(6):1013-69. PubMed ID: 10557544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.